Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation
Ocular inflammation is one of the most common symptom of eye disorders and diseases. The therapeutic management of this inflammation must be rapid and effective in order to avoid deleterious effects for the eye and the vision. Steroidal (SAID) and non-steroidal (NSAID) anti-inflammatory drugs and im...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/6/570 |
| _version_ | 1797564720938483712 |
|---|---|
| author | Roseline Mazet Josias B. G. Yaméogo Denis Wouessidjewe Luc Choisnard Annabelle Gèze |
| author_facet | Roseline Mazet Josias B. G. Yaméogo Denis Wouessidjewe Luc Choisnard Annabelle Gèze |
| author_sort | Roseline Mazet |
| collection | DOAJ |
| description | Ocular inflammation is one of the most common symptom of eye disorders and diseases. The therapeutic management of this inflammation must be rapid and effective in order to avoid deleterious effects for the eye and the vision. Steroidal (SAID) and non-steroidal (NSAID) anti-inflammatory drugs and immunosuppressive agents have been shown to be effective in treating inflammation of the ocular surface of the eye by topical administration. However, it is well established that the anatomical and physiological ocular barriers are limiting factors for drug penetration. In addition, such drugs are generally characterized by a very low aqueous solubility, resulting in low bioavailability as only 1% to 5% of the applied drug permeates the cornea. The present review gives an updated insight on the conventional formulations used in the treatment of ocular inflammation, i.e., ointments, eye drops, solutions, suspensions, gels, and emulsions, based on the commercial products available on the US, European, and French markets. Additionally, sophisticated formulations and innovative ocular drug delivery systems will be discussed. Promising results are presented with micro- and nanoparticulated systems, or combined strategies with polymers and colloidal systems, which offer a synergy in bioavailability and sustained release. Finally, different tools allowing the physical characterization of all these delivery systems, as well as in vitro, ex vivo, and in vivo evaluations, will be considered with regards to the safety, the tolerance, and the efficiency of the drug products. |
| first_indexed | 2024-03-10T19:01:59Z |
| format | Article |
| id | doaj.art-2ad5311072344498bb86984a6c007c09 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T19:01:59Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-2ad5311072344498bb86984a6c007c092023-11-20T04:20:00ZengMDPI AGPharmaceutics1999-49232020-06-0112657010.3390/pharmaceutics12060570Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical EvaluationRoseline Mazet0Josias B. G. Yaméogo1Denis Wouessidjewe2Luc Choisnard3Annabelle Gèze4DPM, UMR CNRS 5063, ICMG FR 2607, Faculty of Pharmacy, University of Grenoble Alpes, 38400 St Martin d’Hères, FranceUFR/SDS, University Joseph Ki-Zerbo, Ouagadougou 03 BP 7021, Burkina FasoDPM, UMR CNRS 5063, ICMG FR 2607, Faculty of Pharmacy, University of Grenoble Alpes, 38400 St Martin d’Hères, FranceDPM, UMR CNRS 5063, ICMG FR 2607, Faculty of Pharmacy, University of Grenoble Alpes, 38400 St Martin d’Hères, FranceDPM, UMR CNRS 5063, ICMG FR 2607, Faculty of Pharmacy, University of Grenoble Alpes, 38400 St Martin d’Hères, FranceOcular inflammation is one of the most common symptom of eye disorders and diseases. The therapeutic management of this inflammation must be rapid and effective in order to avoid deleterious effects for the eye and the vision. Steroidal (SAID) and non-steroidal (NSAID) anti-inflammatory drugs and immunosuppressive agents have been shown to be effective in treating inflammation of the ocular surface of the eye by topical administration. However, it is well established that the anatomical and physiological ocular barriers are limiting factors for drug penetration. In addition, such drugs are generally characterized by a very low aqueous solubility, resulting in low bioavailability as only 1% to 5% of the applied drug permeates the cornea. The present review gives an updated insight on the conventional formulations used in the treatment of ocular inflammation, i.e., ointments, eye drops, solutions, suspensions, gels, and emulsions, based on the commercial products available on the US, European, and French markets. Additionally, sophisticated formulations and innovative ocular drug delivery systems will be discussed. Promising results are presented with micro- and nanoparticulated systems, or combined strategies with polymers and colloidal systems, which offer a synergy in bioavailability and sustained release. Finally, different tools allowing the physical characterization of all these delivery systems, as well as in vitro, ex vivo, and in vivo evaluations, will be considered with regards to the safety, the tolerance, and the efficiency of the drug products.https://www.mdpi.com/1999-4923/12/6/570SAIDNSAIDimmunosuppressant drugstopical ophthalmic formulationrecent advancesbiopharmaceutical evaluation |
| spellingShingle | Roseline Mazet Josias B. G. Yaméogo Denis Wouessidjewe Luc Choisnard Annabelle Gèze Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation Pharmaceutics SAID NSAID immunosuppressant drugs topical ophthalmic formulation recent advances biopharmaceutical evaluation |
| title | Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation |
| title_full | Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation |
| title_fullStr | Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation |
| title_full_unstemmed | Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation |
| title_short | Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation |
| title_sort | recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and their biopharmaceutical evaluation |
| topic | SAID NSAID immunosuppressant drugs topical ophthalmic formulation recent advances biopharmaceutical evaluation |
| url | https://www.mdpi.com/1999-4923/12/6/570 |
| work_keys_str_mv | AT roselinemazet recentadvancesinthedesignoftopicalophthalmicdeliverysystemsinthetreatmentofocularsurfaceinflammationandtheirbiopharmaceuticalevaluation AT josiasbgyameogo recentadvancesinthedesignoftopicalophthalmicdeliverysystemsinthetreatmentofocularsurfaceinflammationandtheirbiopharmaceuticalevaluation AT deniswouessidjewe recentadvancesinthedesignoftopicalophthalmicdeliverysystemsinthetreatmentofocularsurfaceinflammationandtheirbiopharmaceuticalevaluation AT lucchoisnard recentadvancesinthedesignoftopicalophthalmicdeliverysystemsinthetreatmentofocularsurfaceinflammationandtheirbiopharmaceuticalevaluation AT annabellegeze recentadvancesinthedesignoftopicalophthalmicdeliverysystemsinthetreatmentofocularsurfaceinflammationandtheirbiopharmaceuticalevaluation |